Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) said the National Medical Products Administration accepted drug registration applications for two drugs developed by two of its subsidiaries, a Monday bourse filing said.

The NMPA accepted the application of Polymyxin B sulfate for Injection of Guilin Pharmaceutical, while Shanghai Zhaohui Pharmaceutical had its application for Labetalol Hydrochloride Injection accepted by the regulator.

Polymyxin B sulfate for Injection is meant for the treatment of gram-negative bacterial infections while the Labetalol Hydrochloride Injection is for the treatment of severe hypertension.